Nemiralisib (GSK2269557): A Comprehensive Monograph on a Discontinued PI3Kδ Inhibitor

Executive Summary

Nemiralisib (GSK2269557) is an investigational small molecule drug developed by GlaxoSmithKline (GSK) as a potent and highly selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ).[1] Designed for inhaled administration, its primary therapeutic objective was the treatment of inflammatory respiratory diseases, with a principal focus on Chronic Obstructive Pulmonary Disease (COPD) and a secondary, mechanism-based exploration in the rare primary immunodeficiency, Activated PI3Kδ Syndrome (APDS).[1] The biological rationale for targeting PI3Kδ was robust, supported by evidence of pathway upregulation in COPD and direct genetic validation from APDS, a condition caused by gain-of-function mutations in the target enzyme.[3]

Early-phase clinical development was promising, demonstrating that inhaled nemiralisib could successfully engage its target in the human lung, leading to a dose-dependent reduction in key biomarkers of PI3Kδ activity.[5] However, this biochemical success failed to translate into clinical benefit. The development program was ultimately halted following the termination of a large, dose-ranging Phase IIb clinical trial (NCT03345407) in patients with acute exacerbations of COPD.[6] An interim futility analysis of this study revealed a comprehensive lack of efficacy across all doses tested, with no improvement in the primary endpoint of lung function (FEV1) or in key secondary endpoints such as the rate of re-exacerbations.[4] Furthermore, the drug exhibited a challenging safety profile at higher doses, characterized by a dose-dependent increase in post-inhalation cough.[4] Parallel investigations in APDS also failed to demonstrate target engagement or clinical efficacy, suggesting a fundamental issue with the therapeutic approach or delivery modality in diseased lungs.[3]

The discontinuation of nemiralisib was driven by this clear clinical failure, which occurred concurrently with a major strategic R&D reprioritization at GSK. During the 2017-2019 period, the company shifted its focus away from respiratory diseases towards oncology and immunology, leading to the culling of numerous pipeline assets, including nemiralisib.[6] The confluence of definitive negative clinical data and this evolving corporate strategy sealed the fate of the program. This report provides an exhaustive analysis of nemiralisib, from its molecular characteristics and pharmacological profile to a detailed deconstruction of its clinical trial results and the dual factors that precipitated its discontinuation.

Molecular Profile and Physicochemical Properties

Nomenclature and Chemical Identifiers

To establish the precise identity of the molecule, a comprehensive list of its nomenclature and registry identifiers is essential.

• Generic Name: Nemiralisib (United States Adopted Name / International Nonproprietary Name [INN]).[6]
• Developmental Codes: The compound was primarily known by its GlaxoSmithKline development code, GSK2269557. Variations used during its investigation include GSK-2269557, GSK-2269557A, and the radiolabelled form, [14C]-GSK2269557.[1]
• Registry Numbers:
• DrugBank Accession Number: DB16253.[10]
• CAS Number: 1254036-71-9 (for the free base form).[10]
• UNII (Unique Ingredient Identifier): OEP8JJ3OZR.[10]
• Systematic (IUPAC) Names:
• Free Base: 6-(1H-indol-4-yl)-4-(5-{[4-(propan-2-yl)piperazin-1-yl]methyl}-1,3-oxazol-2-yl)-1H-indazole.[10]
• Hydrochloride Salt: 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole hydrochloride.[13]

Chemical Structure and Properties

Nemiralisib is a new molecular entity classified as a small molecule drug.[1] Its structure incorporates several heterocyclic ring systems, placing it within multiple chemical classes, including indazoles, indoles, oxazoles, piperazines, and pyrazoles.[1]

• Chemical Formula: $C_{26}H_{28}N_{6}O$.[10]
• Molecular Weight:
• Average Weight: 440.551 g/mol.[10]
• Monoisotopic Weight: 440.232459546 g/mol.[10]
• Physicochemical Parameters: The molecule's physical properties are critical determinants of its pharmaceutical behavior. Key parameters are summarized below:

Property	Value	Source
Water Solubility	0.0571 mg/mL	ALOGPS 10
logP (Lipophilicity)	3.79	ALOGPS 10
pKa (Strongest Acidic)	11.32	Chemaxon 10
pKa (Strongest Basic)	7.82	Chemaxon 10
Polar Surface Area	76.98 $Å^2$	Chemaxon 10
Lipinski's Rule of Five	Yes	Chemaxon 10
Bioavailability (Predicted)	1	Chemaxon 10

The very low water solubility is a significant characteristic for an inhaled drug, as dissolution in the lung's epithelial lining fluid is a prerequisite for target engagement. Conversely, its compliance with Lipinski's Rule of Five suggests properties generally favorable for membrane permeation and absorption.[10]

Pharmaceutical Formulations

Nemiralisib was developed in several forms to optimize its delivery and stability.

• Salt Forms: The molecule was investigated as a free base (CAS: 1254036-71-9), a hydrochloride (HCl) salt (CAS: 1254036-77-5), and a succinate salt.[6] The choice of salt form is a critical aspect of pharmaceutical development, influencing properties such as solubility, stability, and manufacturability. The succinate salt was used in at least one clinical trial formulation administered via the DISKUS inhaler.[14]
• Inhaled Formulations: As a therapy for respiratory diseases, nemiralisib was formulated as a dry powder for inhalation (DPI). This powder consisted of the active pharmaceutical ingredient blended with excipients, specifically lactose and magnesium stearate.[4] Two primary inhaler devices were used during its clinical development:

1. Diskus DPI: An earlier device used in some studies.[14]
2. Ellipta DPI: A newer generation device that was later adopted. A dedicated Phase I study (NCT03189589) demonstrated that the Ellipta formulation yielded an improved aerodynamic particle size distribution, with approximately 6-fold and 2-fold increases in very fine particle mass and fine particle mass, respectively, compared to the Diskus formulation. This optimization was intended to enhance drug deposition deep within the lungs and increase local bioavailability.[15]

The deliberate effort to improve the delivery formulation from the Diskus to the Ellipta device underscores an acknowledgment of the challenges posed by the drug's physicochemical properties, particularly its poor water solubility. Enhancing the fine particle fraction was a logical and necessary step to maximize the amount of drug reaching the target tissue. However, the ultimate failure of the large-scale COPD trial, which utilized the optimized delivery system, indicates that improved formulation alone was insufficient to elicit a clinical response. This outcome suggests that the therapeutic hypothesis was flawed or that even with enhanced delivery, therapeutically relevant concentrations could not be achieved or sustained within the complex, inflamed microenvironment of a diseased lung. This latter possibility is echoed in the findings from the APDS trial, where investigators speculated that the drug was not retained in structurally damaged lungs for a sufficient duration.[3]

Pharmacodynamics and Mechanism of Action

The PI3Kδ Pathway as a Therapeutic Target

The rationale for developing nemiralisib is rooted in the specific biological role of its target, the delta isoform of phosphoinositide 3-kinase (PI3Kδ).

• Role of PI3Kδ: PI3Kδ is a lipid kinase that is highly and preferentially expressed in leukocytes (cells of the immune system).[13] Its primary function is to catalyze the phosphorylation of phosphatidylinositol (4,5)-bisphosphate ($PIP_2$) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate ($PIP_3$).[3] This signaling event is a critical node in pathways that regulate the activation, proliferation, migration, and function of multiple immune cell types, including neutrophils, T lymphocytes, and B lymphocytes.[4]
• Rationale in Respiratory Disease: The PI3Kδ pathway's central role in immunity makes it a compelling target for inflammatory diseases. The rationale for its inhibition in COPD was twofold. First, the PI3Kδ pathway has been shown to be upregulated in neutrophils isolated from COPD patients, suggesting it is a driver of the aberrant inflammation characteristic of the disease.[4] Second, strong genetic evidence comes from Activated PI3Kδ Syndrome (APDS), a rare monogenic disorder caused by gain-of-function mutations in the genes encoding PI3Kδ. Patients with APDS suffer from severe immune dysregulation and recurrent, debilitating respiratory infections, providing powerful human genetic validation for the pathway's importance in lung immunity.[3] The central therapeutic hypothesis was that by selectively inhibiting PI3Kδ in the lungs, nemiralisib could act as a targeted immunomodulatory agent, dampening the excessive inflammation associated with COPD exacerbations and potentially improving immune cell function.[4]

Target Potency, Selectivity, and In Vitro Activity

Medicinal chemistry efforts for nemiralisib resulted in a molecule with a highly optimized profile for its intended target.

• High Potency: Nemiralisib is a potent inhibitor of PI3Kδ, exhibiting a pKi of 9.9.[2] The pKi is the negative logarithm of the inhibition constant ($K_i$), meaning this value corresponds to a sub-nanomolar affinity for the target enzyme, a hallmark of a highly potent drug candidate.
• Exceptional Selectivity: A critical feature of nemiralisib is its high selectivity for the δ isoform over other class I PI3K isoforms. In vitro assays demonstrated over 1000-fold selectivity against PI3Kα ($pIC_{50}$=5.3), PI3Kβ ($pIC_{50}$=5.8), and PI3Kγ ($pIC_{50}$=5.2).[18] This selectivity is paramount for safety. The PI3Kα and PI3Kβ isoforms are ubiquitously expressed and are central to fundamental cellular processes such as insulin signaling, glucose metabolism, and cell growth. Inhibition of these isoforms is associated with significant toxicities, such as hyperglycemia and hypertension, which have limited the development of pan-PI3K inhibitors. By specifically targeting the leukocyte-restricted δ isoform, nemiralisib was designed to minimize these on-target, off-isoform side effects.
• Cellular Activity: The molecule's potency was confirmed in a cellular context. In assays using human peripheral blood mononuclear cells (PBMCs), nemiralisib inhibited the production of interferon-gamma (IFNγ) with a $pIC_{50}$ of 9.7, demonstrating its ability to modulate immune cell function effectively in vitro.[18]

Evidence of In Vivo Target Engagement

A crucial step in the early clinical development of any targeted therapy is to confirm that the drug can reach its target in humans and exert the expected biological effect. Nemiralisib successfully cleared this hurdle.

• Sputum Biomarker Modulation: A clinical study in healthy smokers provided direct evidence of target engagement in the lung. Following up to 14 days of treatment with increasing doses of inhaled nemiralisib, analysis of induced sputum samples showed a dose-dependent reduction in the levels of $PIP_3$, the direct enzymatic product of PI3Kδ activation.[5] A maximum placebo-corrected reduction of 36% (90% CI, 11%-64%) was observed after 14 days of treatment. This finding was a critical proof-of-concept, confirming that the inhaled drug was not only delivered to the lung but was also biologically active at its site of action, successfully modulating the intended biochemical pathway.[5]

The clinical development of nemiralisib presents a stark example of the translational chasm that frequently plagues drug development. From a molecular and early clinical perspective, the drug was a success. It was a potent and exquisitely selective molecule designed against a well-validated biological target.[2] The early human studies provided clear and unambiguous evidence of in vivo target engagement, demonstrating a reduction in the key downstream biomarker, $PIP_3$, in the target organ.[5] This successful outcome at the biochemical level, however, failed to translate into any meaningful clinical benefit in large-scale patient trials for either COPD or APDS.[3] This disconnect suggests that the initial therapeutic hypothesis—that inhibiting the PI3Kδ pathway and reducing $PIP_3$ levels in the lung would be sufficient to meaningfully alter the complex, multifactorial pathophysiology of a COPD exacerbation—was ultimately incorrect. The link between this proximal biomarker modulation and the desired clinical outcomes of improved lung function and reduced exacerbations was not as robust as anticipated. It is plausible that in the context of established COPD, the PI3Kδ pathway is either a less dominant driver of clinical symptoms than other inflammatory pathways or that its inhibition is insufficient to overcome redundant signaling mechanisms that sustain the disease process.

Clinical Pharmacokinetics and Metabolism

Absorption and Bioavailability

The pharmacokinetic profile of nemiralisib was characterized through a series of Phase I studies in healthy volunteers, employing various administration routes to build a comprehensive understanding of its absorption, distribution, metabolism, and excretion (ADME) properties.

• Inhaled Administration: Following administration via a dry powder inhaler, nemiralisib was rapidly absorbed from the lungs into the systemic circulation. The maximum observed plasma concentration ($C_{max}$) was achieved very quickly, with a median time to $C_{max}$ ($T_{max}$) of approximately 0.08 hours (about 5 minutes).[21]
• Oral Contribution to Systemic Exposure: For inhaled drugs, a portion of the dose is inevitably deposited in the oropharynx and subsequently swallowed. A dedicated study (NCT02691325) using an oral charcoal block was conducted to quantify this effect. The results indicated that approximately 23% of the total systemic exposure (as measured by the area under the concentration-time curve, AUC) after inhalation from the Ellipta device was attributable to gastrointestinal absorption of the swallowed drug fraction.[22] This is a significant finding, as this orally absorbed fraction contributes to systemic drug levels and potential side effects without providing therapeutic benefit in the lungs.
• Physiologically Based Pharmacokinetic (PBPK) Modeling: GSK extensively utilized PBPK modeling to integrate data from intravenous, oral, and inhaled administrations. This approach allowed for the development of a mechanistic model that could predict drug concentrations in both plasma and various tissues, providing a more nuanced understanding of its disposition than plasma measurements alone could offer.[16]

Distribution

Once absorbed, nemiralisib distributed throughout the body, with a notable preference for the target organ.

• High Lung vs. Plasma Concentrations: A key objective for an inhaled therapy is to achieve high concentrations at the site of action while minimizing systemic exposure. Analysis of bronchoalveolar lavage (BAL) fluid from healthy smokers treated with nemiralisib confirmed the successful achievement of this goal. Drug concentrations were found to be substantially higher in the lungs compared to plasma: approximately 32-fold higher in the BAL fluid component and 214-fold higher in the cellular fraction of the BAL.[5] This demonstrated effective targeting and retention within the lung compartment.
• Systemic Tissue Distribution: Despite its preferential concentration in the lungs, PBPK modeling predicted that nemiralisib also distributes systemically into other tissues. The liver, muscle, and adipose tissue were identified as important sites of distribution following absorption into the bloodstream.[16]

Metabolism and Elimination

The clearance of nemiralisib from the body is primarily driven by hepatic metabolism.

• Metabolism: The major route of clearance for nemiralisib is metabolism mediated by the Cytochrome P450 3A4 (CYP3A4) enzyme system in the liver.[25]
• Drug-Drug Interactions: Given the reliance on CYP3A4 for its clearance, a clinical drug-drug interaction study (NCT03398421) was conducted. This trial evaluated the effect of co-administration with itraconazole, a potent inhibitor of CYP3A4, on the pharmacokinetics of nemiralisib. The study confirmed the potential for clinically relevant interactions with strong CYP3A4 modulators.[6]
• Elimination Half-life and Accumulation: Nemiralisib exhibits a long terminal elimination half-life ($T_{1/2}$), estimated to be approximately 40 hours.[21] This long half-life means that the drug is cleared slowly from the body, leading to accumulation with repeated daily dosing. Clinical studies confirmed this, showing an accumulation of approximately 3- to 4.5-fold in plasma exposure after 14 days of once-daily treatment.[5] Pharmacokinetic modeling indicated that a steady-state concentration was achieved by day 6 or 7 of continuous dosing.[21]

The pharmacokinetic profile of nemiralisib, particularly its long half-life, can be viewed as a double-edged sword. On one hand, the ~40-hour half-life and predictable accumulation were advantageous, strongly supporting a convenient once-daily dosing regimen, which is highly desirable for patient adherence in chronic diseases like COPD.[5] On the other hand, this same property presents a potential liability. The dose-ranging COPD trial revealed a clear signal for dose-dependent adverse events, most notably post-inhalation cough, which became significantly more prevalent at the highest doses tested.[4] For a drug with a long half-life, the onset of such an adverse event means that it will take a considerable amount of time for the drug to clear from the system, potentially prolonging the patient's discomfort or risk. This accumulation, coupled with the evidence of systemic distribution, increases the potential for both local and systemic side effects. This dynamic may have created a significant therapeutic window challenge: the doses required to potentially achieve efficacy may have pushed the accumulating drug concentrations into a range that caused unacceptable local tolerability issues, thereby narrowing or eliminating the path to a successful dose. The ultimate failure to identify an effective and well-tolerated dose in the comprehensive Phase IIb study supports this interpretation.[8]

Clinical Development Program Overview

The clinical development of nemiralisib followed a logical, phased approach, progressing from initial human safety and pharmacokinetic studies to larger trials designed to evaluate efficacy in specific patient populations. The program was comprehensive but ultimately unsuccessful, with key trials being terminated or failing to meet their objectives, leading to the discontinuation of the drug's development. A summary of the key clinical trials is presented in the table below.

Trial ID	Phase	Status	Condition(s)	Purpose	Key Findings / Outcome	Source Snippets
NCT03345407	2	Terminated	Chronic Obstructive Pulmonary Disease (COPD)	Treatment, Dose-Finding	Failed to meet primary endpoint (FEV1); no improvement in re-exacerbations. Development discontinued based on futility analysis.	4
NCT02593539	2	Completed	Activated PI3K-delta Syndrome (APDS)	Treatment	Safe and well-tolerated, but no convincing evidence of target engagement or clinical efficacy. Development for APDS suspended.	3
NCT03398421	1	Completed	Healthy Subjects	Drug-Drug Interaction	Assessed the pharmacokinetic effect of the potent CYP3A4 inhibitor itraconazole on nemiralisib. Results were posted.	6
NCT03315559	1	Completed	Healthy Subjects	ADME	Determined the absorption, distribution, metabolism, and excretion profile using a radiolabelled microtracer dose.	6
NCT03189589	1	Completed	Healthy Subjects	PK / Formulation	Assessed the pharmacokinetics and safety of a new dry powder formulation in the Ellipta inhaler, supporting its use in Phase IIb.	15
NCT02691325	1	Completed	Healthy Subjects	PK / Bioavailability	Evaluated single and repeat doses via the Ellipta DPI and quantified the oral contribution to systemic exposure using a charcoal block.	22

The development trajectory began with a series of foundational Phase I studies in healthy volunteers. These trials successfully established the drug's safety profile at various doses, characterized its pharmacokinetic properties (including its long half-life and accumulation), evaluated the performance of new inhaler formulations, and investigated its metabolic pathways and potential for drug-drug interactions.[15] With this supportive Phase I data package, GSK advanced nemiralisib into two parallel Phase II programs to test its efficacy in patients: a large, pivotal study in COPD and a smaller, exploratory study in the rare disease APDS.[1] It was at this critical efficacy-testing stage that the program faltered, as neither trial was able to demonstrate a clinical benefit, leading to the cessation of all development activities.[3]

Efficacy and Safety in Chronic Obstructive Pulmonary Disease (COPD)

The Pivotal Phase IIb Study (NCT03345407): Design and Rationale

The cornerstone of the nemiralisib development program for COPD was the NCT03345407 study, a large-scale, multicenter trial designed to definitively assess the drug's dose-response relationship, efficacy, and safety.[6] The study was a Phase IIb, randomized, double-blind, placebo-controlled, parallel-group trial that enrolled 938 patients (aged 40-80 years with a significant smoking history) who were experiencing an acute moderate or severe exacerbation of COPD requiring standard-of-care treatment.[4]

The rationale was to intervene during a period of heightened inflammation to see if nemiralisib could improve recovery and prevent subsequent events. Patients were randomized to receive either placebo or one of six active doses of inhaled nemiralisib (12.5 µg, 50 µg, 100 µg, 250 µg, 500 µg, or 750 µg) administered once daily for a 12-week treatment period, followed by a 12-week follow-up period. All treatment was given in addition to the patient's standard-of-care therapy.[4]

Analysis of Efficacy Failure

The trial failed to demonstrate any clinical benefit for nemiralisib across all doses tested. The results represented a comprehensive efficacy failure.

• Primary Endpoint: The primary endpoint was the change from baseline in post-bronchodilator forced expiratory volume in 1 second ($FEV_1$) at week 12. The analysis showed no statistically significant or clinically meaningful difference between any of the nemiralisib treatment groups and the placebo group.[4] For the highest dose tested (750 µg), the posterior adjusted median difference versus placebo was a negligible -0.004 Liters (95% Credible Interval: -0.051 L to 0.042 L), indicating a complete lack of effect on lung function.[8]
• Secondary Endpoints: The lack of efficacy extended to all key secondary endpoints. There were no observed differences between nemiralisib and placebo in the rate of subsequent moderate or severe exacerbations (re-exacerbations) during the treatment period.[4] Similarly, no benefits were seen in various patient-reported outcomes, including scores from the Exacerbations of Chronic Pulmonary Disease Tool (EXACT), the COPD Assessment Test (CAT), and the St. George's Respiratory Questionnaire-COPD (SGRQ-C).[4] This consistent lack of effect across objective physiological measures, clinical event rates, and subjective patient assessments reinforced the conclusion of futility.

Safety and Tolerability Profile

While nemiralisib failed on efficacy, it also presented a challenging tolerability profile, particularly at higher doses.

• Adverse Events (AEs): The overall incidence of AEs was higher in the two highest dose groups (500 µg and 750 µg) compared to placebo and lower doses. In the 750 µg group, 62% of patients reported a treatment-emergent AE, compared to 47% in the placebo group.[4]
• Post-Inhalation Cough: The most common adverse event associated with nemiralisib was post-inhalation cough. This AE was clearly dose-related. In the 500 µg and 750 µg dose groups, 35% of patients experienced cough, a seven-fold increase compared to the 5% incidence in the placebo group.[4] The cough was typically reported to occur within one minute of inhalation and last for up to three minutes.[4]
• Bronchospasm: Bronchospasm was identified as an adverse event of special interest. It was reported infrequently but occurred exclusively in patients receiving active treatment at doses of 250 µg or higher, leading to treatment discontinuation for five individuals. This signal had not been prominently noted in previous, smaller studies.[4]

The Decision to Terminate

Given the emerging data, GSK made the decision to halt the study prematurely. Recruitment was stopped after a planned interim futility analysis was conducted. The results of this analysis indicated that there was a very low probability of the study meeting its primary success criteria if it were to continue to completion.[4] This definitive clinical data served as the primary trigger for the termination of the NCT03345407 trial and, by extension, the entire nemiralisib program for COPD.

The results from this large, well-designed, dose-ranging study revealed what can be described as an inverted therapeutic window. In a successful drug development program, as the dose increases, efficacy should rise before the incidence of dose-limiting toxicities becomes unacceptable. For nemiralisib in COPD, the opposite occurred. The efficacy curve across a wide range of doses was flat and indistinguishable from placebo.[4] Concurrently, the toxicity curve, driven primarily by dose-dependent cough, was clearly rising.[4] This created a situation where increasing the dose worsened tolerability without providing any corresponding clinical benefit. Such a profile is unviable for a therapeutic agent, making the decision to terminate the program based on the futility analysis a scientifically and commercially sound one.

Investigation in Activated PI3Kδ Syndrome (APDS)

Rationale for Study in a Rare Disease

In parallel with the large COPD program, GSK initiated a smaller, more targeted study of nemiralisib in patients with Activated PI3Kδ Syndrome (APDS). APDS is a rare, primary inborn error of immunity caused by autosomal dominant gain-of-function mutations in one of the two genes encoding the PI3Kδ enzyme ($PIK3CD$ or $PIK3R1$).[3] This genetic defect leads to constitutive activation of the PI3Kδ pathway in immune cells, resulting in a complex clinical phenotype characterized by recurrent sinopulmonary infections, bronchiectasis, lymphoproliferation, and immunodeficiency.[3]

The rationale for studying nemiralisib in this population was exceptionally strong. It represented a precision medicine approach, where the drug's specific mechanism of action—the inhibition of PI3Kδ—directly counteracts the underlying molecular pathology of the disease. This provided a "best-case scenario" to demonstrate the drug's biological activity in a human disease context.

Review of the Open-Label Trial (NCT02593539)

The investigation was conducted as a small, open-label trial (NCT02593539). The study enrolled five subjects with a confirmed diagnosis of APDS, who were treated with inhaled nemiralisib for a period of 12 weeks. The primary objectives were to evaluate the safety, systemic exposure, and effects on lung and systemic biomarkers of PI3Kδ pathway activity.[3]

Outcomes: Safety Without Efficacy

The trial demonstrated that nemiralisib was generally safe in this small patient population but failed to show any evidence of biological activity or clinical benefit.

• Safety: The drug had an acceptable safety and tolerability profile. Cough was the most commonly reported adverse event, and no severe adverse events occurred during the study.[3]
• Failure of Target Engagement and Biomarker Response: The most critical finding was a lack of biological effect. The study reported "no convincing evidence of target engagement in the lung" following inhaled dosing.[3] Analysis of induced sputum and blood samples showed no meaningful changes in the levels of the direct biomarker, $PIP_3$, or in downstream inflammatory markers and lymphocyte subsets. Essentially, the drug did not appear to be modulating the target pathway in the intended manner in these patients.[3]
• Pharmacokinetic Anomaly: An unexpected pharmacokinetic finding emerged. The systemic levels of nemiralisib in the APDS subjects were observed to be higher than those seen in previous studies in other populations. The investigators hypothesized that this could be due to the pre-existing structural lung damage and bronchiectasis common in APDS patients. This compromised lung architecture may have prevented the inhaled drug from being retained locally, leading to more rapid and extensive absorption into the systemic circulation, thereby reducing the time and concentration available for local target engagement in the lung.[3]

Suspension of Development

Based on the complete lack of evidence for target engagement or downstream efficacy, the study's authors concluded that the data did not support the hypothesis that inhaled nemiralisib would benefit patients with APDS. Consequently, the clinical development of nemiralisib for this indication was suspended.[3]

The failure of nemiralisib in APDS is particularly illuminating and presents a significant paradox. This was the indication with the most direct and powerful biological rationale, where the drug's mechanism was perfectly matched to the disease's genetic cause. The failure in this context points to a problem more fundamental than a simple mechanism-disease mismatch, as might be argued for a complex, heterogeneous disease like COPD. The investigators' hypothesis provides a compelling explanation: the pathophysiology of the target organ itself actively undermined the drug's intended pharmacokinetic profile. The structural lung damage caused by the disease may have prevented the inhaled drug from being retained locally for a sufficient duration to engage its target effectively. This creates a challenging paradox for drug development: the very disease that makes a patient an ideal candidate for a drug's mechanism of action can simultaneously make them a poor candidate for its route of administration. This experience serves as a critical lesson for the development of inhaled therapies for any disease that causes significant structural lung damage, suggesting that a systemic (e.g., oral) route of administration might be necessary even when the primary target organ is the lung.

Synthesis and Critical Evaluation: The Discontinuation of Nemiralisib

The Clinical Verdict: A Clear Failure of Efficacy

The primary and most direct cause for the discontinuation of the nemiralisib development program was its definitive failure to demonstrate clinical efficacy. This conclusion is not based on ambiguous signals or marginal results but on the unambiguous negative outcome of a large, well-designed, and rigorously conducted Phase IIb trial in its lead indication, COPD. The decision by GSK to halt trial NCT03345407 early, based on a pre-planned interim futility analysis, underscores the clarity of the negative data.[4] The failure was comprehensive, with no benefit observed across the primary endpoint of lung function, the key secondary endpoint of exacerbation reduction, or in any patient-reported outcomes, across a wide spectrum of six different doses.[4] This lack of a dose-response for efficacy, coupled with a clear dose-response for the key adverse event of cough, painted a clear picture of an unviable therapeutic profile.[4]

This clinical verdict was further solidified by the disappointing results from the APDS trial. The failure to demonstrate target engagement or biomarker modulation in this "best-case" patient population—where the drug's mechanism directly opposed the disease's genetic driver—suggested that the issues with nemiralisib were fundamental, relating either to the therapeutic hypothesis or, more likely, the viability of an inhaled delivery approach in structurally compromised lungs.[3]

The Strategic Context: GSK's R&D Reprioritization

The clinical failure of nemiralisib did not occur in a corporate vacuum. Its demise coincided with a period of significant strategic transformation within GSK's pharmaceutical R&D division. Beginning in 2017, under the new leadership of CEO Emma Walmsley, the company initiated a major pipeline overhaul designed to improve R&D productivity and focus investment on areas with the highest potential for growth and scientific innovation.[29] This strategy involved culling a large number of preclinical and clinical programs—over 80 by early 2019—and concentrating 80% of the R&D budget into four priority therapeutic areas: HIV/infectious diseases, oncology, and immuno-inflammation, with respiratory being a notable area of de-emphasis.[9]

In a February 2019 update on this R&D restructuring, GSK explicitly named nemiralisib as one of the assets being discontinued. It was part of a "cull" of respiratory medicines that also included another Phase II COPD drug, danirixin. This move was framed as part of a deliberate redirection of the R&D engine away from its former heartland of respiratory medicine and into the targeted new growth areas.[6]

Final Synthesis: The Confluence of Clinical Failure and Corporate Strategy

The discontinuation of nemiralisib is best understood as the result of a powerful confluence of these two factors: unequivocal clinical failure and a concurrent, top-down corporate strategic shift. The negative data from the NCT03345407 futility analysis provided the clear, data-driven, scientific rationale to terminate the program. There was no viable path forward from a clinical or regulatory perspective. Simultaneously, the drug's status as a respiratory asset made it a prime candidate for discontinuation under GSK's new R&D strategy, which was actively de-prioritizing the therapeutic area.

This intersection of events created what might be termed a "low bar for failure." For a drug candidate in a non-priority therapeutic area, any significant negative data is highly likely to be a terminal event, prompting a swift decision to cut losses and reallocate resources. In contrast, a similar clinical setback for an asset in a high-priority area, such as oncology, might have triggered additional investment in biomarker analysis, subgroup identification, or exploration of combination therapies in an attempt to salvage the program. For nemiralisib, the clinical failure was clear, but the strategic context ensured that the decision to terminate would be swift, decisive, and final. Its story is therefore not just a case study in clinical trial failure but also a clear example of how modern pharmaceutical portfolio management operates, where go/no-go decisions are a function of both scientific data and the dynamic strategic priorities of the parent organization.

Works cited

1. Nemiralisib - GlaxoSmithKline - AdisInsight, accessed October 27, 2025, https://adisinsight.springer.com/drugs/800035208
2. Nemiralisib (Standard) | PI3K Inhibitor | MedChemExpress, accessed October 27, 2025, https://www.medchemexpress.com/nemiralisib-standard.html
3. An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome | Request PDF - ResearchGate, accessed October 27, 2025, https://www.researchgate.net/publication/368790829_An_open_label_trial_of_nemiralisib_an_inhaled_PI3_kinase_delta_inhibitor_for_the_treatment_of_Activated_PI3_kinase_Delta_Syndrome
4. Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8184152/
5. Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/30886125/
6. Nemiralisib - Drug Targets, Indications, Patents - Patsnap Synapse, accessed October 27, 2025, https://synapse.patsnap.com/drug/81d32bc5278c409e8562b953ed81ab20
7. Nemiralisib Terminated Phase 2 Trials for Chronic Obstructive Pulmonary Disease (COPD) Treatment | DrugBank Online, accessed October 27, 2025, https://go.drugbank.com/drugs/DB16253/clinical_trials?conditions=DBCOND0031289&phase=2&purpose=treatment&status=terminated
8. Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study. - SciSpace, accessed October 27, 2025, https://scispace.com/pdf/nemiralisib-in-patients-with-an-acute-exacerbation-of-copd-2smr6t1z1v.pdf
9. Pharma companies clear the R&D decks in Q4 - pharmaphorum, accessed October 27, 2025, https://pharmaphorum.com/news/pharma-companies-clear-the-rd-decks-in-q4
10. Nemiralisib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 27, 2025, https://go.drugbank.com/drugs/DB16253
11. NEMIRALISIB - precisionFDA, accessed October 27, 2025, https://precision.fda.gov/ginas/app/ui/substances/9ca04303-56e4-4fb9-b8fb-ac7e555c5c90
12. Advanced Filter - DrugBank, accessed October 27, 2025, https://go.drugbank.com/unearth/q?c=_score&d=down&page=76&query=ester+cl+rose+gln&searcher=drugs
13. Nemiralisib HCl | GSK-2269557 HCl | 1254036-77-5 - MedKoo Biosciences, accessed October 27, 2025, https://www.medkoo.com/products/6819
14. An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial - Dove Medical Press, accessed October 27, 2025, https://www.dovepress.com/an-inhaled-pi3k-inhibitor-improves-recovery-in-acutely-exacerbating-co-peer-reviewed-fulltext-article-COPD
15. Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/31076203/
16. Physiologically Based Pharmacokinetic Modelling of Inhaled ... - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8813803/
17. Nemiralisib 2HCl | CAS 1254036-71-9 | InvivoChem, accessed October 27, 2025, https://invivochem.net/nemiralisib.html
18. Nemiralisib (GSK2269557 free base) | PI3K Inhibitor - MedchemExpress.com, accessed October 27, 2025, https://www.medchemexpress.com/GSK2269557-free-base.html
19. nemiralisib | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 27, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9425
20. Nemiralisib hydrochloride (GSK2269557) | PI3K Inhibitor | MedChemExpress, accessed October 27, 2025, https://www.medchemexpress.com/nemiralisib-hydrochloride.html
21. Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK2269557 (Nemiralisib) Administered Via Dry Powder Inhaler to Healthy Japanese Subjects - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/30303626/
22. Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/30055824/
23. (PDF) Physiologically Based Pharmacokinetic Modelling of Inhaled Nemiralisib: Mechanistic Components for Pulmonary Absorption, Systemic Distribution, and Oral Absorption - ResearchGate, accessed October 27, 2025, https://www.researchgate.net/publication/354210369_Physiologically_Based_Pharmacokinetic_Modelling_of_Inhaled_Nemiralisib_Mechanistic_Components_for_Pulmonary_Absorption_Systemic_Distribution_and_Oral_Absorption
24. Physiologically Based Pharmacokinetic Modelling of Inhaled Nemiralisib: Mechanistic Components for Pulmonary Absorption, Systemic Distribution, and Oral Absorption - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/34458976/
25. Study Details | NCT03398421 | A Study to Evaluate the Effect of ..., accessed October 27, 2025, https://clinicaltrials.gov/study/NCT03398421
26. NCT03345407 | Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) | ClinicalTrials.gov, accessed October 27, 2025, https://clinicaltrials.gov/study/NCT03345407
27. Search results for [14C]-praliciguat - Clinical Trials Registry - ICH GCP, accessed October 27, 2025, https://ichgcp.net/amp/clinical-trials-registry/research/list?intr=%5B14C%5D-praliciguat&page=7
28. The COPD Pipeline XXXVII - PMC - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5870742/
29. GlaxoSmithKline stops development of 30 pipeline prospects, mulls sale of rare disease unit as new CEO Walmsley makes her mark | Fierce Biotech, accessed October 27, 2025, https://www.fiercebiotech.com/biotech/gsk-stops-development-30-pipeline-prospects-mulls-sale-rare-disease-unit-as-new-ceo